...
首页> 外文期刊>The Annals of Thoracic Surgery: Official Journal of the Society of Thoracic Surgeons and the Southern Thoracic Surgical Association >Thoracic Bleeding Complications in Patients With Venovenous Extracorporeal Membrane Oxygenation
【24h】

Thoracic Bleeding Complications in Patients With Venovenous Extracorporeal Membrane Oxygenation

机译:静脉体外膜氧合患者的胸腔出血并发症

获取原文

摘要

BackgroundPatients with respiratory failure are treated more frequently with venovenous extracorporeal membrane oxygenation (vv-ECMO). These patients are at?risk for bleeding due to complex multifactorial coagulation disorders resulting from the extracorporeal circulation.MethodsA retrospective analysis was conducted of prospectively collected data on all patients requiring vv-ECMO between December 2010 and December 2016. End points were the incidence, consequence, and in-hospital mortality of patients with thoracic bleeding complications.ResultsThe study included 418 patients (aged 50 ± 16.5 years) requiring vv-ECMO. In 23.2% (n?= 97) of patients, relevant hemorrhage was documented. Thoracic bleeding developed in 40 patients (41.2%), followed by diffuse (21.6%), cerebral (14.4%), gastrointestinal (6.2%), cannulation site (6.2%), and other bleeding locations. Thoracic bleeding complications occurred spontaneously (40%), postoperatively (37.5%), after interventions (20%), and after trauma (2.5%). A thoracic operation was performed in 60% (n?= 24) of these patients, and a repeated operation due to bleeding was necessary in 45.8%. Mean ECMO duration (18.6 ± 16.8 days;p?= 0.035) and hospital length of stay (58 ± 50 days;p?= 0.002) were significantly longer than that in patients without bleeding. In-hospital mortality was significantly higher in patients with thoracic bleeding complications (52.5%) than in patients without bleeding complications (32.7%;p?= 0.013).ConclusionsThoracic bleeding complications were observed in 9.6% of patients and represented the most frequent bleeding complication during vv-ECMO treatment. Almost 60% of patients required surgical revision, and nearly half of these patients underwent a repeated operation. Because mortality is high in these patients, vv-ECMO should be performed in only centers experienced with thoracic surgery.
机译:背景患有呼吸衰竭的患者接受静脉静脉体外膜氧合(vv-ECMO)的治疗更加频繁。这些患者因体外循环引起的复杂的多因素凝血障碍而处于出血危险中。方法对2010年12月至2016年12月间所有需要vv-ECMO的患者的前瞻性数据进行回顾性分析。终点为发生率,结果结果该研究包括418例需要vv-ECMO的患者(年龄50±16.5岁)。在23.2%(n?= 97)的患者中,记录了相关的出血。 40例患者发生胸腔出血(41.2%),然后是弥漫性(21.6%),脑部(14.4%),胃肠道(6.2%),插管部位(6.2%)和其他出血部位。胸腔出血并发症自发发生(40%),术后(37.5%),干预后(20%)和创伤后(2.5%)。在这些患者中,有60%(n = 24)进行了胸腔手术,而由于出血而需要重复手术的比例为45.8%。平均ECMO持续时间(18.6±16.8天; p?= 0.035)和住院时间(58±50天; p?= 0.002)明显长于无出血患者。胸腔出血并发症患者的院内死亡率(52.5%)明显高于无出血并发症的患者(32.7%; p?= 0.013)。结论在9.6%的患者中观察到胸腔出血并发症是最常见的出血并发症在vv-ECMO治疗期间。几乎60%的患者需要手术矫正,其中近一半的患者接受了重复手术。由于这些患者的死亡率很高,因此vv-ECMO应该仅在经历过胸外科手术的中心进行。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号